Satya Kumar Lalam

Satya Kumar Lalam

Auto-generated profile, based on publicly available information

Satya Kumar Lalam

Department of Pathology, Microbiology and Immunology University of Nebraska Medical Center Omaha Nebraska USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2026 in Health Science Reports
Verified
Journal Article
Open access
KKKajal Kamra
Kajal Kamra
SLSatya Kumar Lalam
Satya Kumar Lalam
SSShefali Srivastava
Shefali Srivastava
Madan Kumar ArumugamMadan Kumar Arumugam
Madan Kumar Arumugam
LBLOKESH KUMAR BOOPATHY
LOKESH KUMAR BOOPATHY
SSSabarinath Peruvemba Subramanian
Sabarinath Peruvemba Subramanian
Background and Aims: Extracellular vesicles (EVs) are nanoscale carriers, including exosomes, microvesicles, and apoptotic bodies, that mediate intercellular communication by transporting proteins, nucleic acids, lipids, and metabolites. They regulate immunity, tissue repair, and cell differentiation. Increasing evidence highlights their dual roles in disease, where they may promote tumor growth and immune evasion but also serve as diagnostic and therapeutic tools. This review synthesizes advances in EV biology, their roles in health and disease, and their therapeutic potential. Methods: We conducted a narrative review of recent literature, focusing on EV isolation methods, biological functions, and clinical applications. Sources were selected to capture both mechanistic insights and translational perspectives. Results: Advances in isolation technologies, from ultracentrifugation to microfluidics, have improved the precision of EV characterization. EVs exhibit distinct molecular signatures, positioning them as promising biomarkers in cancer, cardiovascular, neurodegenerative, autoimmune, and infectious diseases. Mechanistic studies demonstrate their roles in immune modulation, tissue remodeling, and regeneration. As therapeutic agents, EVs show promise as drug delivery systems and as platforms for gene and immunotherapies, offering enhanced targeting and reduced toxicity compared to synthetic nanoparticles. Engineered EVs and hybrid EV–liposome systems further expand their applications, though challenges persist in scalability, standardization, and safety. Conclusion: EVs are central mediators of intercellular communication with transformative potential in diagnostics and therapeutics. Their biological properties position them as valuable biomarkers and delivery vehicles in precision medicine. Overcoming translational challenges, such as immunogenicity, oncogenic risks, and manufacturing limitations, will be essential for their successful clinical integration.

15 March 2024 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
MSMounica Soma
Mounica Soma
JSJody Scebold
Jody Scebold
AVAngela Vasa
Angela Vasa
TFTeresa Ann Fitzgerald
Teresa Ann Fitzgerald
KTKate Tyner
Kate Tyner
MAMuhammad Salman Ashraf
Muhammad Salman Ashraf
Objective:The study examined resources needed by Infection Preventionists (IP) to address infection prevention and control (IPC) program gaps.Design:A 49-question survey.Setting:Licensed Critical Access Hospitals (CAHs) in Federal Emergency Management Area (FEMA) Region VII.Participants:IP at licensed CAHs.Methods:The survey conducted between December 2020 and January 2021 consisted of questions focusing on four categories including IPC program infrastructure, competency-based training, audit and feedback, and identification of high-risk pathogens/serious communicable diseases (HRP/SCD). An IPC score was calculated for each facility by totaling “Yes” responses (which indicate best practices) to 49 main survey questions. Follow-up questions explored the resources needed by the CAHs to implement or further strengthen best practices and mitigate IPC practice gaps. Welch t-test was used to study differences in IPC practice scores between states.Results:50 of 259 (19.3%) CAHs participated in the survey with 37 (14.3%) answering all 49 questions. CAHs responding to all questions had a median IPC score of 35. There was no significant difference between IPC practice scores of CAHs in NE and IA. The top three IPC gaps were absence of drug diversion program (77%), lack of audits and feedback for insertion and maintenance of central venous catheters (76%), and missing laboratory risk assessments to identify tests that can be offered safely for patients under investigation for HRP/SCD (76%). Standardized audit tools, educational resources, and staff training materials were cited as much-needed resources.Conclusion:IPC practice gaps exist in CAHs. Various resources are needed for gap mitigation.